as on November 21, 2025 at 11:39 pm IST
Day's Low
Day's High
5.39%
Downside
0.32%
Upside
52 Week's Low
52 Week's High
71.12%
Downside
83.19%
Upside
Check Replimune Group Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$705.2M
EPS (TTM)
-2.8128
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-313.0M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-96.24%
Compare market cap, revenue, PE, and other key metrics of Replimune Group Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $705.2M | -81.98% | NA | 0.00% | |
| BUY | $42.6B | 410.98% | -16.34 | -264.83% | |
| BUY | $60.9B | 257.49% | 1439.88 | 1.36% | |
| BUY | $107.9B | 96.24% | 29.59 | 31.35% | |
| BUY | $74.5B | 42.08% | 16.84 | 32.13% |
The Replimune Group Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Replimune Group Inc investment value today
Current value as on today
₹90,067
Returns
Returns from Replimune Group Inc Stock
Dollar Returns*
₹6,085 (+6.09%)
Based on 15 analysts
93.33%
Buy
6.67%
Hold
0.00%
Sell
Based on 15 analysts, 93.33% of analysts recommend a 'BUY' rating for Replimune Group Inc. Average target price of $12.57
Get share price movements and forecasts by analysts on Replimune Group Inc.
What analysts predicted
26.17%UPSIDE
Target Price
$12.57
Current Price
$9.28
Analyzed by
15 Analysts
Target
$12.57
Replimune Group Inc target price $12.57, a slight upside of 26.17% compared to current price of $9.28. According to 15 analysts rating.
Search interest for Replimune Group Inc Stock has increased by 191% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:191% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 20 October
Mon, 06:49 PM
-Replimune's stock rises 105% after FDA accepts resubmission for RP1 therapy in advanced melanoma, with a decision due by April 2026.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 1 month, REPL stock has moved up by 11.2%
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 20.08 Cr → 22.22 Cr (in ₹), with an average increase of 9.6% per quarter
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 954.6% return, outperforming this stock by 1006.9%
Retail Holding Unchanged
![]()
Retail Investor holdings remained unchanged at 31.34% of holdings in Sep 2025 quarter
Against Peers
![]()
In the last 1 year, One 97 Communications Ltd has given 51.9% return, outperforming this stock by 79.4%
Promoter Holding Unchanged
![]()
Promoters holdings remained unchanged at 68.55% of holdings in Sep 2025 quarter
Against Peers
![]()
In the last 3 years, Firstsource Solutions Ltd has given 243.3% return, outperforming this stock by 258.5%
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 170.5% return, outperforming this stock by 189.0%
Price Dip
![]()
In the last 6 months, REPL stock has moved down by -34.8%
Profit Down
![]()
Netprofit is down for the last 2 quarters, 2.49 Cr → 0.95 Cr (in ₹), with an average decrease of 61.9% per quarter
| Organisation | Replimune Group Inc |
| Headquarters | 500 Unicorn Park Drive, Woburn, MA, United States, 01801 |
| Industry | Health Technology |
| CEO | Dr. Sushil Patel Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Shawn Glidden J.D. | Senior VP & General Counsel |
Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
Ms. Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management |
Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer |
Mr. Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer |
Mr. Christopher Sarchi | Chief Commercial Officer |
Dr. Sushil Patel Ph.D. | CEO & Director |
Ms. Emily Luisa Hill | Chief Financial Officer |
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
Mr. Philip Astley-Sparke F.S.A. | Executive Chairman |
Replimune Group Inc share price today is $9.28 as on . Replimune Group Inc share today touched a day high of $9.31 and a low of $8.78.
Replimune Group Inc share touched a 52 week high of $17 on and a 52 week low of $2.68 on . Replimune Group Inc stock price today i.e. is trending at $9.28,which is 45.41% down from its 52 week high and 246.27% up from its 52 week low.
Replimune Group Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Replimune Group Inc (REPL) shares with as little as ₹89.642 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹896.42 in Replimune Group Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Replimune Group Inc share’s latest price of $9.28 as on November 21, 2025 at 11:39 pm IST, you will get 1.0776 shares of Replimune Group Inc. Learn more about
fractional shares .
Replimune Group Inc stock has given -81.98% share price returns and 19.25% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?